

News Release

April 22, 2025 KH Neochem Co., Ltd.

KH Neochem to Exhibit at BIO KOREA 2025

KH Neochem Co., Ltd. (TSE: 4189, President and CEO: Michio Takahashi, "KH Neochem") will be exhibiting at the "BIO KOREA 2025 International Convention^{**1}" held in Seoul, Korea, from May 7-9, 2025 (booth No. M7).

"BIO KOREA*" is an international conference for the biotechnologies, bio pharmaceuticals, and healthcare sectors, held annually in Korea since 2006. The event brings together pharmaceutical and biotech companies, as well as research institutions from around the world, with the aim of revitalizing the bio-health industry and promoting its global development. In addition to showcasing the latest technologies, business trends and products, BIO KOREA also facilitates business matching and networking opportunities with experts and companies.

KH Neochem aims to contribute to the advancement of biopharmaceuticals through its proprietary glycan technologies. At BIO KOREA, we will exhibit at our own booth, where we will showcase our original glycan product, GlyMuch™, including research-use glycan reagents and glycan remodeling services for proteins.

• For more details about the event, please visit the official website.

About Glycans

KH Neochem, aiming to achieve our "VISION 2030**," has designated "Environment," "Healthcare," and "Electronics" as strategic domains. "KH i-Lab," a newly established research hub, has been dedicated to accelerating research and development and driving creation of new businesses by leveraging an open innovation strategy. In the healthcare domain, KH Neochem has focused on the potential of glycans, and has developed proprietary glycans and manufacturing technologies.

In living organisms, glycans are linked to proteins and lipids on cell surfaces and within cells. Due to modulating the function and stability of the binding substances, glycoproteins and glycolipids influence various biological events such as cell adhesion and differentiation. It has been known that many diseases and disorders are associated with glycan abnormalities. Along with nucleic acids and proteins, these glycans comprise "the third life chain" because of their involvement in various vital phenomena.

As the third life chain, glycans have been actively investigated in life science fields to elucidate vital biological processes and develop new drugs, but artificial synthesis of glycans is difficult because of the great diversity of glycan structures. Ensuring a stable and sufficient supply of glycans remains a



major challenge, not only for academic research but also for industrial applications. KH Neochem has developed original glycan manufacturing technology to ensure a stable supply and is accelerating marketing efforts to explore partners for value creation through glycan applications.

[EVENT INFORMATION]

Event name	BIO KOREA 2025 International Convention
Organizer	BIO KOREA Organizing Committee
Date	May 7(WED)-9(FRI) 2025
Venue	Conference Room (3, 4F)
	COEX Convention & Exhibition Center
	513 Yeongdong-daero, Gangnam District, Seoul, South Korea
Registration	Please check the official website for registration.
	https://www.biokorea.org/index.asp
Booth No.	M7
Exhibits	1.N-Glycan Reagents "GlyMuch™" for Research-use
	2.Improving the pharmacokinetics of peptides
	3.Synthesis of homogeneous antibodies and antibody-drug conjugates
	(ADCs) via glycosylation"

■ About Glycans

https://www.khneochem.co.jp/en/solution/features/glycans/

■ GlyMuch[™] glycans by KH Neochem

https://www.khneochem.co.jp/en/solution/features/glycans/service/

- * 「BIO KOREA 2025 International Convention」 https://www.biokorea.org/index.asp
- ** [VISION2030]

https://ssl4.eir-parts.net/doc/4189/ir material4/152214/00.pdf



[About KH Neochem]

Corporate Overview (as of December 31, 2024)

Company name: KH Neochem Co., Ltd. President & CEO: Michio Takahashi

Establishment: December 2010 (Our predecessor Kyowa Yuka, was established in November

1966)

Capital: 8.8bn JPY

Head office: 2-3-1, Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-0022, Japan

Number of employees: 829 (Consolidated)

Business: Research, manufacture, and sale of petrochemical products

Main products: Performance materials (refrigeration lubricant raw materials, cosmetics ingredients) Electronics materials (high-purity solvents for semiconductors and flat panel

displays)

Basic chemicals (solvents for coatings and inks, raw materials for plasticizer)

Group Companies: Kurogane Kasei Co., Ltd. / Kurogane Fines Inc. / KH Neochem Americas, Inc. /

Shanghai Seika Trading Co., Ltd.

Corporate History

1948 Kyowa Sangyo Co., Ltd., the forerunner of Kyowa Hakko Kogyo Co., Ltd., began Japan's first mass production of Acetone and Butyl alcohol from molasses using fermentation technology.

1949 Established Kyowa Hakko Kogyo Co., Ltd. (now Kyowa Kirin Co., Ltd.)

1966 Established Kyowa Yuka Co., Ltd. (A subsidiary chemical manufacturer of Kyowa Hakko Kogyo Co., Ltd.)

Name changed to Kyowa Hakko Chemical Co., Ltd. through joint investment of the Chemical Department of Kyowa Hakko Co., Ltd. and Kyowa Yuka Co., Ltd.

2011 Spun off from Kyowa Hakko Kirin Group (now Kyowa Kirin Group) as an independent entity.

2012 Name changed to KH Neochem Co., Ltd.

2016 Listed on the First Section of the Tokyo Stock Exchange.

2018 Formulated VISION 2030

2019 Established open innovation hub KH i-Lab

2022 Moved to the Prime Market following the restructuring of the Tokyo Stock Exchange's market segments.

For inquiries regarding this matter, please contact:

Corporate Communications and Investor Relations

KH Neochem Co., Ltd.

kouhou@khneochem.co.jp

•KH i-Lab:KH Neochem innovation Laboratory

innovation@khneochem.co.jp